

Product Specification Sheet

**11-Beta-hydroxysteroid dehydrogenase-2 (11 $\beta$ -HSD2) Antibodies**

Cat. # BHSD23-S	Rabbit Anti-Human 11 $\beta$ -HSD2 antiserum #3	<b>SIZE:</b> 100 ul
Cat. # BHSD23-A	Rabbit Anti-Human 11 $\beta$ -HSD2 IgG #3 (Affinity pure)	<b>SIZE:</b> 100 ug
Cat. # BHSD23-P	Human 11 $\beta$ -HSD2 Control/blocking peptide	<b>SIZE:</b> 100 ug

11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) is a microsomal short chain dehydrogenase/reductase (SDR) which catalyzes the inter-conversion of biologically active glucocorticoid (cortisol in human and corticosterone in rats and mice) and inactive glucocorticoid (cortisone and 11-dehydrocorticosterone). Two tissue specific isoforms (**11 $\beta$ -HSD1** and **11 $\beta$ -HSD2**) of 11 $\beta$ -HSD with two different functions regarding glucocorticoid availability, have been identified. The decreased 11 $\beta$ -hydroxy oxidation of cortisol results in Apparent Mineralocorticoid Excess (AME) disorder which is manifested by hypertension, hypokalemia, low plasma renin activity, and responsiveness to spironolactone. AME is principally a disorder of juveniles and children with this condition oxidize cortisol to cortisone poorly but carry out the reverse process unimpaired. AME arises from mutations in the 11 $\beta$ -HSD2 gene. The glucocorticoids can also be produced locally by **11 $\beta$ -HSD1** and increased visceral accumulation of glucocorticoids results in visceral obesity, insulin resistant diabetes, hyperlipidemia and hyperphagia.

**11 $\beta$ HSD-2** (rat 400-aa, mouse 396-aa, human 405-aa) is a ~41 kDa glycosylated membrane-protein present in the endoplasmic reticulum (ER). The N-terminal and C-terminal (catalytic domain) of 11 $\beta$ -HSD2 are in the lumen and cytoplasm of ER, respectively. 11 $\beta$ -HSD2 irreversibly catalyzes the dehydrogenation of active 11 $\beta$ -hydroxycorticoids before they occupy mineralocorticoid receptors (MR) and thus confers aldosterone selectivity for inherently nonselective MR. The enzyme is expressed in a wide array of tissues, with highest level mineralocorticoid target cells such as the renal and outer medullary collecting ducts. In mouse, rat and Human, the over-all aa seq of 11 $\beta$ -HSD2 is >80% identical. In mouse, the over-all aa seq of 11 $\beta$ -HSD2 is >80% identical to that of 11 $\beta$ -HSD2.

**Source of Antigen and Antibodies**

<b>Antigen</b>	A 19-aa peptide (designated BHSD23-P or control peptide) Gene Accession # P80365, human 11 $\beta$ -HSD2 (1) conjugated to KLH Epitope location ~ N-terminal
<b>Ab Host/type</b>	Rabbit, Polyclonal unpurified antiserum (#BHSD23-S) and IgG, purified over antigen-agarose (Cat # BHSD23-A)
<b>2-Ab</b>	Cat # 20320, goat anti-rabbit IgG-HRP (AP, biotin, FITC conjugates also available).
<b>-ve control</b>	# 20009-1, Rabbit (non-immune) IgG, purified, suitable for ELISA, Western, IHC as -ve control

**Form & Storage of Antibodies/Peptide Control**

**Antiserum (unpurified)**

100ul solution lyophilized powder  
Supplied in Buffer: 0.05% azide  
**Reconstitute powder in 100 ul PBS**

**Affinity pure IgG**

100 ug/100ul solution lyophilized powder  
Supplied in **Buffer:** PBS+0.1% BSA  
**Reconstitute powder in PBS at 1 mg/ml**

**Control/blocking peptide**

100 ug/100 ul solution lyophilized powder  
Supplied in Buffer: PBS pH 7.5,  
**Reconstitute powder in PBS at 1 mg/ml.**

**Storage**

**Short-term:** unopened, undiluted liquid vials at -200C and powder at 4oC or -20oC..

**Long-term:** at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

**Stability:** 6-12 months at -20oC or below.

**Shipping:** 4oC for solutions and room temp for powder

**Recommended Usage**

**Western Blotting** (1:1K-5K for neat serum and 1-10 ug/ml for affinity pure using Chemiluminescence technique) (see refs 2).

**ELISA** (1:10K-1:100K; using 50-100 ng of control peptide/well).

**Histochemistry & Immunofluorescence:** We recommend the use of affinity pure antibody at 2-20 ug/ml (see refs 2).

**Specificity & Cross-reactivity**

The human **BHSD23-P** peptide is not well conserved in mouse and rat 11 $\beta$ -HSD2. We recommend the use of cat # BHD21-A and BHD22-A for rat and mouse 11 $\beta$ -HSD2, respectively. No significant sequence homology of **BHSD23-P** is seen with 11 $\beta$ -HSD1 or other proteins. Control peptide, because of its low mol. Wt (<3 kDa), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10 ug control peptide per 1 ug of aff pure IgG or 1 ul antiserum) to confirm antibody specificity (see detailed protocol at web site)

**General References:** (1) Albiston AL (1994) Mol. Cell. Endocrinol. 105, R11; Mune T (1995) Nat. Genet. 10, 394; Masuzaki (2001) Science 294, 2166; Blum . (2000) BBRC. 276, 428.

*\*This product is for In vitro research use only.*

**Antiserum (unpurified)**

100ul solution lyophilized powder  
Supplied in Buffer: 0.05% azide  
**Reconstitute powder in 100 ul PBS**

BHSD23-S-A-P 71208S

**India Contact:**

**Life Technologies (India) Pvt. Ltd.**

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi - 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444  
Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)